淋巴结清扫范围与食管切除术后总生存改善相关
基于美国国家癌症数据库2006至2012年18777例食管切除术患者,仅37.1%采样15枚以上淋巴结。直接手术者采样25枚以上死亡风险降低最明显(HR 0.77),诱导治疗后采样10或15枚以上即达最佳生存获益;阳性/检查淋巴结比0至0.10者生存获益最大。
要点
- 仅37.1%食管切除术患者采样15枚以上淋巴结,未达NCCN指南推荐。
- 直接手术者采样25枚以上淋巴结死亡风险降低最明显(HR 0.77)。
- 诱导治疗后患者采样10或15枚以上淋巴结即达最佳生存获益。
核心结论
- 直接食管切除术患者检查20至25枚淋巴结可能有额外生存获益,高于现行推荐。
- 仅少数患者符合现行NCCN指南的15枚以上淋巴结采样推荐。
研究设计与样本
- 回顾性队列研究,利用美国国家癌症数据库2006至2012年18777例食管切除术患者数据。
- 采用单因素分析、logistic回归、Cox比例风险模型和Kaplan-Meier分析评估淋巴结采样与总生存关系。
主要发现
- 18777例中仅6961例(37.1%)采样15枚以上淋巴结。
- 直接手术者采样25枚以上淋巴结死亡风险降低最明显(HR 0.77;95%CI 0.67-0.89;p<0.001)。
- 诱导治疗者采样10或15枚以上淋巴结与最佳生存获益相关(HR 0.81;95%CI 0.74-0.90;p<0.001)。
- 阳性/检查淋巴结比为0至0.10者生存获益最大;该比为0者采样20枚以上中位OS 85.3个月,采样1-9枚为52.0个月(p<0.001)。
关键数值与推荐
- NCCN指南推荐食管切除术中采样15枚以上淋巴结。
- 直接手术者采样25枚以上淋巴结死亡风险降低最明显(HR 0.77;95%CI 0.67-0.89;p<0.001)。
- 诱导治疗者采样10或15枚以上淋巴结与最佳生存获益相关(HR 0.81;95%CI 0.74-0.90;p<0.001)。
- 阳性/检查淋巴结比0至0.10与最大生存获益相关。
临床怎么用
- 食管切除术中应争取更广泛的淋巴结采样,直接手术者考虑20至25枚。
- 诱导治疗后患者采样10至15枚以上即可获生存获益,但仍需个体化评估。
- 关注阳性/检查淋巴结比,低比值(0至0.10)提示生存获益最大。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: National Comprehensive Cancer Network (NCCN) guidelines recommend sampling 15 or more lymph nodes during esophagectomy. The proportion of patients meeting this guideline is unknown, as is its influence on overall survival (OS). METHODS: Univariate analysis and logistic regression were performed to identify variables associated with sampling 15 or more lymph nodes among patients undergoing esophagectomy in the National Cancer Data Base (NCDB). The NCCN guideline was evaluated in Cox proportional hazards modeling, along with alternative lymph node thresholds. Positive to examined node (PEN) ratios were calculated, and OS was compared using Kaplan-Meier analysis. RESULTS: From 2006 to 2012, only 6,961 of 18,777 (37.1%) patients undergoing esophagectomy had sampling of 15 or more lymph nodes. Variables associated with sampling 15 or more lymph nodes included income greater than or equal to $38,000, procedure performed in an academic facility, and increasing clinical T and N stages. Induction therapy was associated with a decreased likelihood of 15 or more lymph nodes being sampled. The largest decrease in mortality hazard in patients undergoing upfront esophagectomy was detected when 25 lymph nodes or more were sampled (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.67-0.89; p < 0.001), whereas for patients undergoing induction therapy, sampling of 10 or 15 or more lymph nodes was associated with optimal survival benefit (HR, 0.81; 95% CI, 0.74-0.90; p < 0.001). PEN ratios of 0 to 0.10 were associated with maximum survival benefit among all patients undergoing esophagectomy. For patients with a PEN ratio of 0, increases in OS were detected with higher lymph node sampling (85.3 months for sampling of 20 or more lymph nodes versus 52.0 months for sampling 1-9 lymph nodes; p < 0.001). CONCLUSIONS: For patients undergoing upfront esophagectomy, there may be an increased survival benefit for examining 20 to 25 lymph nodes, which is higher than current recommendations. However, only a minority of patients are meeting current guidelines.
引用
- Samson P, Puri V, Broderick S, et al. Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy. Ann Thorac Surg. 2016. PMID: 28024648. doi:10.1016/j.athoracsur.2016.08.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。